

### **THE AMENDED CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously amended). A method for treating strabismus, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component of a botulinum toxin to thereby treat strabismus wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.
2. (original). The method of claim 1 wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
3. (canceled).
4. (original). The method of claim 1, wherein the botulinum toxin is botulinum toxin type A.
5. (previously amended). A method for treating strabismus, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component of only a botulinum toxin type A, to thereby treat strabismus, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.
- 6-28. (cancelled).
29. (previously amended). A method for treating strabismus, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component from a single botulinum toxin type selected from the group consisting of the botulinum toxin types A, B, C, D, E, F and G to

thereby treat strabismus, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.

30-46. (cancelled).

47. (previously added). The method of claim 5, wherein the neurotoxic component is administered by intramuscular injection.

48-62 (cancelled).

63. (previously added). The method of claim 29, wherein the neurotoxic component is administered by intramuscular injection.

64-77. (cancelled).